- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S5250
| Related Targets | HDAC Caspase Proteasome Secretase MMP HCV Protease Cysteine Protease DPP Tyrosinase Serine Protease |
|---|---|
| Other HIV Protease Inhibitors | Pepstatin A Limonin Temsavir (BMS-626529) Rosamultin Bevirimat Dextran sulfate sodium (DSS) Mericitabine NBD-556 GS-6207 Azvudine |
|
In vitro |
DMSO
: 100 mg/mL
(182.59 mM)
Ethanol : 11 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 547.66 | Formula | C27H37N3O7S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 206361-99-1 | -- | Storage of Stock Solutions |
|
|
| Synonyms | TMC114,DRV | Smiles | CC(C)CN(CC(C(CC1=CC=CC=C1)NC(=O)OC2COC3C2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N | ||
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06139796 | Not yet recruiting | HIV Infections |
PENTA Foundation|AMS-PHPT Research Collaboration|Institut National de la Santé Et de la Recherche Médicale France|Centre Mère et Enfant de la Fondation Chantal Biya|Centre Hospitalier National d''Enfants Albert Royer|University of Zimbabwe Clinical Research Centre (UZCRC)|Baylor College of Medicine |
June 2024 | Phase 1|Phase 2 |
| NCT06005610 | Recruiting | HIV I Infection |
National Institute of Allergy and Infectious Diseases (NIAID) |
January 4 2024 | Phase 2 |
| NCT05506605 | Active not recruiting | HIV-1-infection |
Fundacion Clinic per a la Recerca Biomédica |
December 12 2022 | Phase 4 |
| NCT05197075 | Completed | Human Immunodeficiency Virus (HIV) |
Janssen Research & Development LLC |
August 3 2022 | Phase 1 |
| NCT05378906 | Completed | Healthy |
Janssen Research & Development LLC |
June 7 2022 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.